RxDoctor Payments Data

John Alley, MD

Family Medicine · Marcellus, NYNPI 1598727554

Payments from drug & device makers

$7,351in general payments, 2019–2025

Across 394 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$983
  • GSK$889
  • Lilly USA, LLC$694
  • Pfizer$416
  • AstraZeneca$297
  • plus $3K from 33 others

What the payments were for

  • Speaking & faculty fees$1001%
  • Food & beverage$7,23198%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,351 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$124,937
Medicare patients
255
Services billed
2,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin77$102,804
OzempicSemaglutide62$92,971
EliquisApixaban48$45,051
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$41,001
TrulicityDulaglutide22$26,822
XareltoRivaroxaban31$24,685
Repatha SureclickEvolocumab19$21,368
FarxigaDapagliflozin Propanediol12$19,880
MounjaroTirzepatide15$15,282
Tresiba Flextouch U-200Insulin Degludec12$7,201
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$6,482
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$5,220
Breo ElliptaFluticasone/Vilanterol12$4,700
Albuterol Sulfate HfaAlbuterol Sulfate144$4,227
Rosuvastatin Calcium275$3,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$272$102,80477 claims
Novo NordiskOzempic$1,344$92,97162 claims
PfizerEliquis, Paxlovid$416$47,77959 claims
GSKTrelegy Ellipta, Breo Ellipta$889$45,70164 claims
Lilly USA, LLCTrulicity, Mounjaro$694$42,10437 claims
Johnson & JohnsonXarelto$17$24,68531 claims
AstraZenecaFarxiga$297$19,88012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.

Other family medicine in Marcellus

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →